Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cannabis extract shows promise for rare genetic disorder in new trial

NCT ID NCT07257978

Not yet recruiting Symptom relief Sponsor: Fenix Innovation Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a cannabis plant extract called NTI164, which has very low THC (the compound that causes a high), in 40 females aged 4-25 with Rett syndrome, a rare genetic condition causing severe physical and mental challenges. Participants will receive either NTI164 or a placebo, then switch after a period, to see if the treatment safely reduces symptoms like anxiety, breathing problems, and trouble communicating. The goal is to improve daily life, not to cure the condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETT SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cannabis dependence Rett syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETT SYNDROME RETT SYNDROME WITH PROVEN MECP2 MUTATION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Monash Health

    Clayton, Victoria, 3168, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••